Keep in touch

Advancing innovation, access, and public health

The Medicines Patent Pool is a United Nations backed organisation that offers a public-health driven business model that aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines in developing countries. It was founded in 2010 at the request of the international community through the WHO-based financing mechanism UNITAID. Learn more.

News & Announcements

Medicines Patent Pool, ViiV Healthcare Sign Licence for the Most Recent HIV Medicine to Have Received Regulatory Approval

Access to dolutegravir could improve millions of lives in developing countries 1 APRIL 2014, GENEVA, SWITZERLAND: The Medicines Patent Pool (MPP) and ViiV Healthcare announced a new collaboration on HIV medicines today, signing two licensing agreements to increase access to dolutegravir (DTG), a promising new antiretroviral, for both adult and … Read more

Final Recommendations for the roundtable discussions to EU-Africa Summit Leaders

Health and Pharmaceutical; promoting growth, innovation and access to healthcare and pharmaceuticals through EU-Africa Business Cooperation, including local production of generic medicines in Africa Final recommendations for the roundtable discussions to EU-Africa Summit Leaders: 1 April 2014 The EU-Africa Business Forum recommends: 1. AU – EU political commitment at the … Read more

MPP and Bristol-Myers Squibb Sign Agreement to Further Expand Access to a Key HIV Medicine

12 DECEMBER 2013, GENEVA: The Medicines Patent Pool (MPP) and biopharmaceutical company Bristol-Myers Squibb have signed a licensing agreement to increase access to a key HIV medicine, atazanavir, in 110 developing countries. These countries represent 88.5 percent of people living with HIV/AIDS in developing countries. “This agreement will allow manufacturers … Read more

More news & announcements

Upcoming events

5-6 June 2014

Lyon, France

20-25 July 2014

International AIDS Conference
Melbourne, Australia

The Medicines Patent Pool to participate in the 2014 meeting of HIV professionals from around the world.

Recent Highlights

UNITAID welcomes ViiV latest collaboration with MPP

Read the full statement on the UNITAID’s website.

Expressions of Interest

Invitation to Sub-License
MPP now invites Expressions of Interest from potential sub-licensees for licences to manufacture and sell formulations containing dolutegravir in adults and paediatrics in the respective Territory.
Instructions available on the Expression of Interest page.